Genetic Susceptibility and Survival: Application to Breast Cancer

Journal of the American Statistical Association

Volumn 95, Issue 449, 2000, Pages 28-42

  Iversen, Edwin S ^a   Parmigiani, Giovanni ^a   Berry, Donald A ^b   Schildkraut, Joellen M ^c  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Breast cancer susceptibility genes; Latent variables; Markov chain Monte Carlo; Survival analysis

Indexed keywords

EID: 0442325144     PISSN: 01621459     EISSN: 1537274X     Source Type: Journal    
DOI: 10.1080/01621459.2000.10473896     Document Type: Article

References (54)

1. Berry, D. A., Parmigiani, G., Sanchez, Schildkraut, J., and Winer, E. (1997), “Probability of Carrying a Mutation of Breast-Ovarian Cancer Gene BRCAI Based on Family History" Journal of the National Cancer Institute, 89, 227-238.
2. Claus, E. B., Risch, N., and Thompson, W. D. (1991), "Genetic Analysis of Breast Cancer in the Cancer and Steroid Hormone Study,” American Journal of Human Genetics, 48, 232-242.
3. Claus, E. B., Risch, N., and Thompson, W. D. (1994), “Autosomal Dominant Inheritance of Early-Onset Breast Cancer: Implications for Risk Prediction." Cancer, 73, 643-651.
4. Claus, E. B., Schildkraut, J. M., Thompson, W. D., and Risch, N. J. (1996), ‘The Genetic Attributable Risk of Breast and Ovarian Cancer," Cancer, 77, 2318-2324.
5. Clayton, D. G. (1991), “A Monte Carlo Method for Bayesian Infcrcnce in Frailty Models," Biometrics, 47, 467-485.
6. Couch, F. J., DcShano, M. L., Blackwood, M. A., Calzonc, K., Stopfer, J., Campcau, L., Ganguly, A., Rebbcck, T., Weber, B. L., Jablon, L., Cobleigh, M. A., Hoskins, K., and Garber, J. E. (1997). “BRCA1 Mutations in Women Attending Clinics That Evaluate the Risk of Breast Cancer,” New England Journal of Medicine, 336, 1409-15.
7. Cox, D. R. (1972). “Regression Models and Life Tables.” Journal of the Royal Statistical Society. Ser. B 34, 187-220.
8. Ford, D., and Easton, D. F. (1995). "The Genetics of Breast and Ovarian Cancer,” Br J Cancer, 72, 805-812.
9. Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Dcvilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., Sobol, H., Teare, M. D., Struewing, J., Arason, A., Schemeck, S., Peto, J., Rebbeck, T. R., Tonin, P., Neuhauscn, S., Barkardottir, R., Eyfjord, J., Lynch, H., Ponder, B. A. J., Gaythcr, S. A., Birch, J. M., Lindblom, A., Stoppa-Lyonnet, D., Bignon, Y., Borg, A., Hamann, U., Haites, N., Scott, R. J., Maugard, C. M., Vasen, H., Seitz, S., Cannon-Albright, L. A., Schofield, A., Zelada-Hedman, M., and the Breast Cancer Linkage Consortium (1998), "Genetic Heterogeneity and Penetrance Analysis of the BRCAI and BRCA2 Genes in Breast Cancer Families,” Am, J. Hum. Genet, 62. 676-689.
10. Futreal, P. A., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, K., Tavtigian, S., Bennett, L. M., Haugen-Strano, A., Swensen, J., Miki, Y., Eddington, K., McClure, M., Frye, C., Weavcr-Feldhaus, J., Ding, W., Gholami, Z., Socderkvist, P., Terry, L., Jhanwar, S., Berchuck, A., Iglehart, J. D., Marks, J., Ballinger, D. G., Barrett, J. C., Skolnick, M. H., Kamb, A., Wiseman, R. (1994), “BRCAI Mutations in Primary Breast and Ovarian Carcinomas,” Science, 226, 120-122.
11. Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C., and Mulvhill, J. J. (1989), “Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who are Being Examined Annually," Journal of the National Cancer Institute, 81, 1879-1886.
12. Gauderman, W. J., and Thomas, D. C. (1994), “Censored Survival Models for Genetic Epidemiology: A Gibbs Sampling Approach,” Genetic Epidemiology, 11, 171-188.
13. Gilks, W. R., Richardson, S., and Spiegelhalter, D. J. (Eds.) (1996). Markov Chain Monte Carlo in Practice, London: Chapman and Hall.
14. Gilks, W. R., and Roberts, G. O. (1996), "Strategies for Improving MCMC," in Markov Chain Monte Carlo in Practice, eds. W. R. Gilks, S. Richardson, and D. J. Spiegelhalter, London: Chapman and Hall, pp. 89-114.
15. Hastings, W. K. (1970), “Monte Carlo Sampling Methods Using Markov Chains and Their Applications," Biometrika, 57, 97-109.
16. Heidelberger, P., and Welch, P. (1983), "Simulation Run Length Control in the Presence of an Initial Transient," Operations Research. 31, 1109-1144.
17. Hilscnbcck, S. G., Wenger, C. R., Reynolds, L. P., Rojas, L. C., and Osborne, C. K. (1997), "Early Results of Genetic Testing for Breast Cancer Susceptibility," Breast Cancer Research and Treatment, 46, 38.
18. Houwing-Duistermaat, J. J. (1997). Statistical Methods for Family Data. Leiden: Leiden University Press.
19. Hunt, S. C., Williams, R. R., and Barlow, G. K. (1986), "A Comparison of Positive Family History Definitions for Defining Risk of Future Disease," Journal of Chronic Diseases, 39(10), 809-21.
20. Ivcrsen, Jr., E. S., Parmigiani, G., and Berry, D. (1998). “Validating Bayesian Prediction Models: A Case Study in Genetic Susceptibility to Breast Cancer," in Case Studies In Bayesian Statistics, Vol. 4, pp. 321-338.
21. Jain, M., and Miller, A. B. (1994), “Pre-Morbid Body Size and the Prognosis of Women with Breast Cancer,” Int J Cancer, 59, 363-8.
22. Johannsson, O., Ranstam, J., Borg, A., and Olsson, H. (1998), “Survival of BRCAI Breast and Ovarian Cancer Patients: A Population-Based Study from Southern Sweden,” Lancet, 351, 304-305.
23. Kalbfleisch, J. D. (1978), "Non-Parametric Bayesian Analysis of Survival Time Data.” Journal of the Royal Statistical Society, Ser. B, 40, 214-221.
24. Kce, F., Collins, B. J., and Patterson C. C. (1991), “Prognosis in Familial Non-Polyposis Colorectal Cancer," Gut, 33(6), 787-90.
25. Lange, K. (1997), Mathematical and Statistical Methods for Generic Analysis, Berlin: Springer.
26. Lee, J., Wacholder, S., Struewing, J., McAdams, M., Pee, D., Brody, L., Tucker, M., and Hartgc, P. (1999), “Survival After Breast Cancer in Ashkenazi Jewish BRCAI and BRCA2 Mutation Carriers,” Journal of the National Cancer Institute, 19, 259-263.
27. Lee, N. C-, Wingo, P. A., Gwinn, M. L., Rubin, G. L., Kendrick, J. S., Webster, L. A., and Ory, H. W. (1987). “The Reduction of Risk of Ovarian Cancer Associated with Oral-Contraceptive Use,” New England Journal of Medicine, 316, 650-655.
28. Li, H., and Thompson, E. A. (1997), “Semiparametric Estimation of Major Gene and Family-Specific Random Effects for Age of Onset,” Biometrics, 53, 282-293.
29. Li, H., Thompson, E. A., and Wijsman, E. M. (1997), “Semiparametric Estimation of Major Gene Effects for Age of Onset,” Genetic Epidemiology, 15(3), 279-298.
30. Markus, J. N., Watson, P., Page, D. L., Narod, S. A., Lenoir, G. M., Tonin, P., Linder-Stephenson, L., Salerno, G., Conway, T. A., and Lynch, H. T. (1996), “Hereditary Breast Cancer: Pathobiology, Prognosis, and BRCAI and BRCA2 Gene Linkage,” Cancer, 77, 697-709.
31. Miki, Y., Swenson, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., Bell, R., Rosenthal, J., et al. (1994), “A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCAI,” Science, 266, 66-71.
32. Murphy, E. A., and Chase, G. A. (1974), Principles of Genetic Counseling. Chicago: Year Book Medical Publishers.
33. Murphy, E. A., and Mutalik, G. S. (1969), “The Application of Bayesian Methods in Genetic Counseling,” Human Heredity, 19. 126-151.
34. National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Program (1997), SEER homepage. http://www-seer.ims.nci.nih.gov.
35. Newman, B., Millikan, R. C., and King, M-C. (1997), “Genetic Epidemiology of Breast and Ovarian Cancers," Epidemiologic Reviews. 19,69-79.
36. Oddoux, C., Struewing, J. P., Clayton, C. M., Neuhauscn, S., Brody, L. C., Kaback, M., Haas, B., Norton, L., Bergen, P., Jhanwar, S., Goldgar, D., Ostrer, H., and Offit, K. (1996), The Carrier Frequency of the BRCA2 6l74delT Mutation Among Ashkenazi Jewish Individuals is Approximately. Nature Genetics, 14, 188-190.
37. Parmigiani, G., Berry, D. A., and Aguilar, O. (1998), “Determining Carrier Probabilities for Breast Cancer Susceptibility Genes BRCAI and BRCA2," American Journal of Human Genetics, 62, 145-158.
38. Perkins, P., Cooksley, C. D., and Cox, J. D. (1996). “Breast Cancer: Is Ethnicity an Independent Prognostic Factor for Survival.” Cancer. 78. 1241-7.
39. Porter, D. E., Cohen, B. B., Wallace, M. R., Smyth, E., Chetty, U., Dixon, J. M., Steel, C. M., and Carter, D. C. (1994), “Breast Cancer Incidence, Penetrance and Survival in Probable Carriers of BRCAI Gene Mutation in Families Linked to BRCAI on Chromosome 17q 12-21 ” British Journal of Surgery, 81, 1512-1515.
40. Porter, D. E., Dixon, M., Smyth, E., and Steel, C. M. (1993), “Breast Cancer Survival in BRCAI Carriers,” Lancet, 341, 184-185.
41. Prentice, R. L. (1982), "Covariate Measurement Errors and Parameter Estimation in a Failure Time Regression Model (corr: V71 p219)," Biometrika, 69. 331-342.
42. Raftery, A. E., and Lewis, S. M. (1996), “Implementing MCMC," See Gilks. Richardson, and Spiegelhalter (1996), pp. 115-127.
43. Reed, T., Wagener, D. K., Donahue, R. P., and Kuller, L. H. (1986), “Family History of Cancer Related to Cholesterol Level in Young Adults,” Genetic Epidemiology, 3, 63-71.
44. Roa, B. B., Boyd, A. A., Volcik, K., and Richards, C. S. (1996), "Ashkenazi Jewish Population Frequencies for Common Mutations in BRCAI and BRCA2,” Nature Genetics. 14, 185-187.
45. Rubin, S. C., Benjamin, I., Behbakht, K., Takahashi, H., Morgan, M. A., LiVolsi, V. A., Berchuck, A., Muto, M. G., Garger, J. E., Wcbcr, B. L., Lynch, H. T., and Boyd, J. (1996). “Clinical and Pathological Features of Ovarian Cancer in Wromen with Germline Mutations of BRCAI," New England Journal of Medicine. 335, 1413-1416.
46. Schildkraut, J. M., and Thompson, W. D. (1988), "Familial Ovarian Cancer: A Population-Based Case-Control Study,” American Journal of Epi-demiology, 128, 456-466.
47. Sharan, S. K., Morimatsu, M., Albrecht, U., Lim, D-S., Regel, E., Dinh, C., Sands, A., Eichele, G., Hasty, P., and Bradley, A. (1997). “Embrionic Lethality and Radiation Hybersensitivity Mediated by Rad51 in Mice Lacking Brca2," Nature, 386, 804-810.
48. Slattery, M. L., and Kerbcr, R. A., (1993), “A Comprehensive Evaluation of Family History and Breast Cancer Risk," Journal of the American Medical Association, 270(13), 1563-8.
49. Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., and Tucker, M. A. (1997), “The Risk of Cancer Associated with Specific Mutations of BRCAI and BRCA2 Among Ashkenazi Jews," New England Journal of Medicine, 336, 1401.
50. Szabo, C. I., and King, M-C. (1997), "Population Genetics of BRCAI and BRCA2," American Journal of Human Genetics, 60, 1013-1020.
51. Thomas, D. C., and Gauderman, W. J. (1996). "Gibbs Sampling Methods in Genetics” in Markov Chain Monte Carlo in Practice, eds, W. R. Gilks, S. Richardson, and D. J. Spiegelhalter, London: Chapman and Hall, pp. 419-440.
52. Tierney, L. (1994, December), “Markov Chains for Exploring Posterior Distributions," (with discussion). The Annals of Statistics, 22, 1701-1762.
53. Watson, P., Marcus, J., and Lynch, H. (1998), “Prognosis of BRCAI Hereditary Breast Cancer," Lancet, 351, 304-305.
54. Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., and Man-gion, J. (1995), “Identification of the Breast Cancer Susceptibility Gene BRCA2,” Nature, 378, 789-92.